Recursion's share price has dropped in recent weeks due to poor clinical trial data, but its most mature assets are not reflective of its current capabilities. Recursion probably needs to advance 5-10 ...
Recursion Pharmaceuticals has an innovative, AI-focused approach to developing drugs. However, the company has yet to find tangible success and faces several headwinds. The stock has substantial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback